It’s been a good month for nail fungus treatment news with another company releasing details of successful clinical trials on a new anti-fungal treatment for onychomycosis. The company NovaBiotics, based in the UK (not be confused with the company in our previous post this month based in the USA) is a biotechnology company currently trialling a new product called Novexatin®.

Novexatin® is a topical, brush on treatment that has just finished Phase IIa clinical trials where 48 patients used the product daily for 28 days. The results confirmed earlier Phase I results showing that the product appears to have no adverse affects on patients from topical application. Earlier nail model trials indicated positive performance in ability to combat nail fungus infection.

The company expects to announce the full data of the completed trials later this year and is currently exploring partnership arrangements for the development and distribution of the treatment. We look forward to seeing this one come to market…